Zurcher Kantonalbank Zurich Cantonalbank Makes New $551,000 Investment in Celcuity, Inc. $CELC

Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the 4th quarter, Holdings Channel.com reports. The fund acquired 5,521 shares of the company’s stock, valued at approximately $551,000.

Several other institutional investors and hedge funds also recently bought and sold shares of CELC. Creative Planning purchased a new position in Celcuity during the second quarter worth $177,000. Rhumbline Advisers boosted its stake in Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after buying an additional 503 shares during the period. XTX Topco Ltd purchased a new position in Celcuity during the second quarter worth $169,000. Quantinno Capital Management LP boosted its stake in Celcuity by 20.7% during the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock worth $3,245,000 after buying an additional 41,756 shares during the period. Finally, Paloma Partners Management Co boosted its stake in Celcuity by 285.8% during the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock worth $1,097,000 after buying an additional 60,849 shares during the period. 63.33% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Richard E. Buller sold 3,000 shares of the business’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total transaction of $330,810.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $745,425.20. The trade was a 30.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on CELC shares. Needham & Company LLC reaffirmed a “buy” rating and set a $122.00 price objective on shares of Celcuity in a research note on Thursday, March 26th. Wolfe Research reaffirmed an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. Citigroup reaffirmed an “outperform” rating on shares of Celcuity in a research note on Monday. Stifel Nicolaus boosted their target price on shares of Celcuity from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research note on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $114.33.

Celcuity Price Performance

Shares of CELC opened at $125.65 on Monday. The firm has a market capitalization of $6.07 billion, a P/E ratio of -33.15 and a beta of 0.09. Celcuity, Inc. has a 12-month low of $9.51 and a 12-month high of $129.09. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20. The firm has a fifty day moving average price of $114.53 and a 200-day moving average price of $102.64.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. Equities research analysts expect that Celcuity, Inc. will post -3.97 earnings per share for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.